Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anxiety
Biotech
Otsuka posts phase 3b ADHD trial win ahead of looming FDA ruling
The phase 3b trial hit its primary endpoint, strengthening the drugmaker’s hand weeks before a potential U.S. launch of the therapy.
Nick Paul Taylor
Jun 25, 2026 9:13am
Vistagen lays off 20% of staff to focus on anxiety candidate
Mar 12, 2026 1:16pm
AtaiBeckley's MDMA drug improves anxiety in ph. 2 trial
Feb 26, 2026 1:32pm
Vistagen's social anxiety disorder asset stumbles in phase 3
Dec 17, 2025 2:44pm
Neuphoria nixes social anxiety program after phase 3 flop
Oct 21, 2025 10:44am
Seaport loads $225M for Karuna vets' voyage to milestones
Oct 21, 2024 8:05am
